Maralixibat comment watch save

  • FDA APPROVAL DATE: 09/28/2021
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    Bile acid binding resins, Cholestyramine, Statins
  • PREGNANCY: Maternal use at the recommended clinical dose of maralixibat is not expected to result in measurable fetal exposure because systemic absorption following oral administration is low.

Please login to view the rest of this drug profile.

Page last updated 07/31/2023

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top